Format

Send to

Choose Destination
Am J Clin Nutr. 2018 Sep 1;108(3):603-610. doi: 10.1093/ajcn/nqy116.

Plasma concentration of trimethylamine-N-oxide and risk of gestational diabetes mellitus.

Li P1,2, Zhong C1,2, Li S1,2, Sun T1,2, Huang H1,2, Chen X1,2, Zhu Y1,2, Hu X1,2, Peng X1,2, Zhang X1,2, Bao W3, Shan Z1,2,4, Cheng J5, Hu FB4,6, Yang N1,2, Liu L1,2.

Author information

1
Department of Nutrition and Food Hygiene, Hubei Key Laboratory of Food Nutrition and Safety.
2
Ministry of Education Key Laboratory of Environment and Health, School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
3
Department of Epidemiology, College of Public Health, University of Iowa, Iowa City, IA.
4
Departments of Nutrition.
5
Shenzhen Center for Disease Control and Prevention, Shenzhen, China.
6
Epidemiology, Harvard TH Chan School of Public Health, Boston, MA.

Abstract

Background:

The microbiota-dependent metabolite trimethylamine-N-oxide (TMAO) has been reported as a novel and independent risk factor for the development of cardiovascular and metabolic diseases, but the association with gestational diabetes mellitus (GDM) remains unclear.

Objective:

The aim of this study was to investigate the association between plasma TMAO concentration and GDM in a 2-phase study.

Design:

A 2-phase design was used in the current study. An initial phase included 866 participants (433 GDM cases and 433 matched controls) with fasting blood samples collected at the time of GDM screening (24-32 wk of gestation). An independent-phase study, with 276 GDM cases and 552 matched controls who provided fasting blood samples before 20 wk of gestation and who had GDM screened during 24-32 wk of gestation, was nested within a prospective cohort study. These 2 studies were both conducted in Wuhan, China, and the incidence of GDM in the cohort study was 10.8%. Plasma TMAO concentrations were determined by stable isotope dilution liquid chromatography-tandem mass spectrometry. GDM was diagnosed according to the American Diabetes Association criteria by using an oral-glucose-tolerance test.

Results:

In the initial case-control study, the adjusted OR of GDM comparing the highest TMAO quartile with the lowest quartile was 1.94 (95% CI: 1.28, 2.93). Each SD increment of ln-transformed plasma TMAO was associated with 22% (95% CI: 5%, 41%) higher odds of GDM. In the nested case-control study, women in the highest quartile also had increased odds of GDM (adjusted OR: 2.06; 95% CI: 1.28, 3.31) compared with women in the lowest quartile, and the adjusted OR for GDM per SD increment of ln-transformed plasma TMAO was 1.26 (95% CI: 1.08, 1.47).

Conclusions:

Consistent findings from this 2-phase study indicate a positive association between plasma TMAO concentrations and GDM. Future studies are warranted to elucidate the underlying mechanisms. This trial was registered at www.clinicaltrials.gov as NCT03415295.

PMID:
30535087
DOI:
10.1093/ajcn/nqy116
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center